Skip to main content
Premium Trial:

Request an Annual Quote

MacroGenics Closes $30.5M Series B VC Round

NEW YORK, Oct. 15 (GenomeWeb News) - MacroGenics, a genomics- and proteomics-tools company co-founded by Lee Hood and Ruedi Aebersold, has collected $30.5 million in a Series B round of private-equity financing, the company said today.

 

Alta Partners and TPG Ventures led the financing, which included investments by Mithra Group, Red Abbey Venture Partners, Emerging Technology Partners, and Series A shareholders InterWest Partners, MPM Capital, OrbiMed, Cogene BioTech Ventures, Vivo Ventures, and Hunt Ventures.

 

MacroGenics, which is also trying to develop antibodies and vaccines to treat cancer, autoimmune disorders, and infectious diseases, will use the cash to support the clinical development of its certain drug candidates and "recent in-licensed opportunities in infectious diseases."

 

The company was founded in 2000.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.